Chemoinformaics analysis of 5-Phenyl-2-oxazolidinone
| Molecular Weight | 163.176 | nRot | 1 |
| Heavy Atom Molecular Weight | 154.104 | nRig | 12 |
| Exact Molecular Weight | 163.063 | nRing | 2 |
| Solubility: LogS | -1.983 | nHRing | 1 |
| Solubility: LogP | 1.43 | No. of Aliphatic Rings | 1 |
| Acid Count | 0 | No. of Aromatic Rings | 1 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 21 | No. of Aliphatic Hetero Cycles | 1 |
| No. of Heavy Atom | 12 | No. of Aromatic Carbocycles | 1 |
| nHetero | 3 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 9 | No. of Saturated Hetero Cycles | 1 |
| No. of Carbon atom | 9 | No. of Saturated Rings | 1 |
| No. of Nitrogen atom | 1 | No. of Arom Atom | 6 |
| No. of Oxygen atom | 2 | No. of Arom Bond | 6 |
| nHA | 2 | APOL | 23.7351 |
| nHD | 1 | BPOL | 12.2029 |
| QED | 0.68 |
| Synth | 2.64 |
| Natural Product Likeliness | 1.01 |
| NR-PPAR-gamma | 0.006 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Rejected |
| Pgp-inh | 0.001 |
| Pgp-sub | 0.017 |
| HIA | 0.06 |
| CACO-2 | -4.409 |
| MDCK | 0.0000769 |
| BBB | 0.963 |
| PPB | 0.710019 |
| VDSS | 1.137 |
| FU | 0.234931 |
| CYP1A2-inh | 0.743 |
| CYP1A2-sub | 0.158 |
| CYP2c19-inh | 0.486 |
| CYP2c19-sub | 0.776 |
| CYP2c9-inh | 0.132 |
| CYP2c9-sub | 0.786 |
| CYP2d6-inh | 0.023 |
| CYP2d6-sub | 0.841 |
| CYP3a4-inh | 0.038 |
| CYP3a4-sub | 0.305 |
| CL | 6.033 |
| T12 | 0.746 |
| hERG | 0.044 |
| Ames | 0.786 |
| ROA | 0.176 |
| SkinSen | 0.425 |
| Carcinogencity | 0.305 |
| EI | 0.084 |
| Respiratory | 0.065 |
| NR-Aromatase | 0.004 |
| Antiviral | No |
| Prediction | 0.871 |